09:20 AM EDT, 10/20/2025 (MT Newswires) -- Radiopharm Theranostics ( RADX ) said Monday it expects to provide topline data readouts from its four lead clinical programs in the near term.

The company also said it plans to begin phase 1 trials for RV01 and RAD402 antibody assets by year-end.

Radiopharm said data from the first two cohorts in its phase 1 trial of RAD 202 in patients with Human Epidermal Growth Factor Receptor 2, or HER2-positive, advanced solid tumors, will likely be available by year-end.

The company also said topline results of a phase 2 trial of RAD101 are expected within H1 of 2026, with preliminary data from three patients in the phase 2b imaging trial showing an uptake in brain metastases from solid tumors.

Shares of the company were down 18% in recent premarket activity Monday.